Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Job posting

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 09, 2023 8:56am

124 Views

Post# 35725637

RE:RE:RE:Job posting

A major positive of this news is that it just may indicate that the BP ( Roche, Merck) may want complete control of the trial as they are providing product. Who knows, but a big positive NR may follow in short order...FDA AA or big partnership or buyout. GL.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects